SGLTs (Sodium-dependent glucose cotransporters) are a family of glucose transporters and contribute to glucose reabsorption.SGLT1 and SGLT2, which belong to the SLC5A gene family, are the two most well-known members of the SGLT family. The two transporters play two major roles in maintaining glucose homeostasis: first, via SGLT1, they absorb glucose from the diet in the small intestine, and second, through SGLT2 and, to a lesser extent, SGLT1, they re-absorb the filtered glucose in the kidney's tubular system, which puts glucose back into the bloodstream and stops urine glucose loss. For diabetes and cardiomyopathy, SGLT1 and SGLT2 have been suggested as a novel therapeutic approach.
Structure | Cat No. | Product Name | CAS No. | Product Description |
---|---|---|---|---|
V78619 | Canagliflozin-d6 (JNJ 28431754-d6) | Canagliflozin-d6 is the deuterated form of Canagliflozin. | ||
V74236 | Empagliflozin-d4 (Empagliflozin-d4; BI 10773-d4) | 2749293-95-4 | Empagliflozin-d4 is the deuterium labelled form of Empagliflozin. | |
V74235 | Enavogliflozin (DWP-16001) | 1415472-28-4 | Enavogliflozin (DWP-16001), an antidiabetic active molecule, is an orally bioactive, first-in-class, selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor. | |
V74243 | Ertugliflozin-d5 (PF-04971729-d5) | 1298086-22-2 | Ertugliflozin-d5 is the deuterated form of Ertugliflozin. | |
V87228 | fluoro-Dapagliflozin | 1181681-43-5 | Fluoro-Dapagliflozin is a structural analog of Dapagliflozin and is a selective SGLT2 inhibitor with Ki values of 5.3 nM and 330 nM for SGLT2 and SGLT1, respectively. | |
V87230 | galacto-Dapagliflozin | 1408245-02-2 | Galacto-dapagliflozin is a selective inhibitor of hSGLT2 with Ki of 25 nM. | |
V74237 | Luseogliflozin hydrate (TS 071 hydrate) | 1152425-66-5 | Luseogliflozin (TS 071) hydrate is a selective, orally bioactive second-generation sodium-glucose cotransporter 2 (SGLT2) inhibitor (antagonist) with IC50 of 2.26 nM. | |
V94315 | Mizagliflozin (sebacate) | 1169392-27-1 | Mizagliflozin sebacate (DSP-3235 sebacate) is a sodium-glucose cotransporter inhibitor with activity in improving cognitive impairment caused by small vessel disease. | |
V74238 | Rongliflozin (DJT1116PG) | 2648020-91-9 | Rongliflozin (DJT1116PG) is a selective, orally bioactive inhibitor of sodium-glucose cotransporter-2 (SGLT-2). | |
V74240 | SGLT1/2-IN-1 | 1673514-65-2 | SGLT1/2-IN-1 is a dual SGLT1/SGLT2 inhibitor. | |
V74239 | SGLT1/2-IN-2 | 2387812-73-7 | SGLT1/2-IN-2 showed potent dual (bifunctional) inhibitory activity (IC50 = 96 nM for SGLT1 and IC50 = 1.3 nM for SGLT2). | |
V87227 | SGLT2-IN-1 | 864070-37-1 | SGLT2-IN-1 (Compound 5) is an inhibitor of sodium-dependent glucose cotransporter (SGLT2) with IC50 of 33 nM. | |
V74245 | Velagliflozin proline | 1539295-26-5 | Velagliflozin proline is an orally bioavailable sodium-glucose cotransporter 2 (SGLT2) inhibitor (antagonist) with antidiabetic activity. | |
V74241 | Velagliflozin proline hydrate | 1661838-94-3 | Velagliflozin proline hydrate is the clinical form of Velagliflozin. | |
V74242 | YM543 free base | 655237-16-4 | YM543 free base is an orally bioavailable sodium-glucose cotransporter (SGLT) 2 inhibitor. | |
V1500 | Empagliflozin (BI 10773) | 864070-44-0 | Empagliflozin (formerly also known as BI1-0773; CE0108; CS0940; PB23119; VA10802; AJ93046; trade name: Jardiance) is a potent and selective SGLT-2 (sodium glucose cotransporter-2) inhibitor with anti-diabetic activity. | |
V1499 | Canagliflozin (JNJ 28431754) | 842133-18-0 | Canagliflozin (formerly TA-7284; JNJ-24831754ZAE; JNJ 28431754-AAA; JNJ-28431754; brand name Invokana)is a highly potent and selective SGLT2 (sodium-glucose transport protein) inhibitor with anti-diabetic activity. | |
V4942 | Phloretin | 60-82-2 | Phloretin (also known as NSC 407292 and RJC 02792), a naturally occuring dihydrochalcone flavonoid mainly found in fruit, leaves, and roots of apple tree, inhibits a variety of transporters such as the monocarboxylate transporters MCT1 and MCT2 (IC50 = 28 and 14 µM, respectively). | |
V5117 | Phlorizin (Floridzin; NSC 2833) | 60-81-1 | Phlorizin (phloridzin), a glucoside of phloretin which is a dihydrochalcone and a family of bicyclic flavonoids, is a potent and non-selective competitive SGLT inhibitor with Kis of 300 and 39 nM for hSGLT1 and hSGLT2, respectively. | |
V1501 | Sotagliflozin (LX4211) | 1018899-04-1 | Sotagliflozin (formerly known as LP-80203; LX4211; LP80203; LX-4211; Zynquista), an antidiabetic drug approved for treating type 1 diabetes in EU, is a potent, orally bioavailable, and dual SGLT1/SGLT2 inhibitor with antidiabetic activity. |